scholarly journals Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients

Stroke ◽  
2012 ◽  
Vol 43 (5) ◽  
pp. 1398-1400 ◽  
Author(s):  
Israel Fernández-Cadenas ◽  
Alberto del Río-Espínola ◽  
Caty Carrera ◽  
Sophie Domingues-Montanari ◽  
Maite Mendióroz ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Tissue Type ◽  
Stroke Patients ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
Mmp9 Gene

Increased tissue-type plasminogen activator activity in orthotopic but not heterotopic liver transplantation: The role of the anhepatic period

Hepatology ◽  
1992 ◽  
Vol 16 (2) ◽  
pp. 404-408 ◽  
Author(s):  
C. Minke Bakker ◽  
Herold J. Metselaar ◽  
Theo N. Groenland ◽  
Maria J. Gomes ◽  
Eduard A. R. Knot ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Plasminogen Activator ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Plasminogen Activator Activity ◽  
Type Plasminogen Activator ◽  
Anhepatic Period

Abstract TMP19: Intravenous Recombinant Tissue-type Plasminogen Activator Use in Young Adults With Acute Ischemic Stroke

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Jodi A Dodds ◽  
Ying Xian ◽  
Shubin Sheng ◽  
Gregg Fonarow ◽  
Ronald A Matsouaka ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Plasminogen Activator ◽  
Older Patients ◽  
Young Patients ◽  
Tissue Type ◽  
Stroke Patients ◽  
Younger Patients ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator

Background: Intravenous recombinant tissue-type plasminogen activator (rt-PA) administration improves outcomes in acute ischemic stroke. However, young patients (<40 years old) presenting with stroke symptoms may experience delays in treatment due to misdiagnosis or a reluctance to treat since they do not fit the profile of a typical stroke patient. Methods: We analyzed data from the large national Get With The Guidelines–Stroke registry for acute ischemic stroke patients hospitalized between January 2009 and September 2015. Multivariable models with generalized estimating equations (GEE) were used to test for differences between younger (age 18-40) and older (age > 40) acute ischemic stroke patients, controlling for patient and hospital characteristics including stroke severity. Results: Of 1,320,965 AIS patients admitted to participating hospitals, 2.3% (30,448) were aged 18-40. Among these patients, 12.5% received rt-PA versus 8.8% of those aged >40 (p<0.001). Of patients arriving within 3.5 hours of symptom onset without contraindications, 68.7% of younger patients received IV rt-PA versus 63.3% of older patients (adjusted OR [aOR] 1.30, 95% CI 1.21 to 1.40), without evidence that age-related differences varied by sex (interaction p-value 0.25). Odds ratios of achieving target door-to-CT times and door-to-needle (DTN) times, and outcomes of rtPA-treated patients, are shown in the Table. Conclusions: Young acute ischemic stroke patients did not receive rt-PA treatment at lower rates than older patients. Outcomes were better and the rate of symptomatic intracranial hemorrhage was lower in the young patients. However, younger patients had significantly longer door-to-CT and DTN times, providing an opportunity to improve the care of these patients.

The role of tissue-type plasminogen activator A-chain domains in plasma clearance

1989 ◽  
Vol 3 (4) ◽  
pp. 207-214 ◽  
Author(s):  
M.J. Browne ◽  
C.G. Chapman ◽  
I. Dodd ◽  
B. Reavy ◽  
A.F. Esmail ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Plasma Clearance ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
A Chain

196 EXPRESSION OF TISSUE-TYPE PLASMINOGEN ACTIVATOR IN OOCYTES AND CUMULUS CELLS FROM MOUSE, PIG, AND COW

2013 ◽  
Vol 25 (1) ◽  
pp. 247
Author(s):  
M. J. Izquierdo-Rico ◽  
M. Moreno-Manrique ◽  
F. A. García-Vázquez ◽  
M. J. Sánchez-Calabuig ◽  
P. Coy
Keyword(s):  
Plasminogen Activator ◽  
Bos Taurus ◽  
Blood Clot ◽  
Cumulus Cells ◽  
Tissue Type ◽  
Clot Lysis ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
Mouse Species

Tissue-type plasminogen activator (tPA) is one of the components of the plasminogen-plasmin (PLG-PLA) system, better known as fibrinolytic system for its role in the blood clot lysis. It has been demonstrated recently that the activation of plasminogen into the protease plasmin during the sperm-oocyte interaction in the pig and cow decreases the percentages of penetration and increases monospermy (Mondéjar et al. 2012). However, in the mouse species, it was showed that PLG-PLA system enhances fertilization (Huarte et al. 1993). Expression of tPA has been described in rat oocytes (Bicsak et al. 1989) and cumulus cells (Ny et al. 1987; O’Connell et al. 1987), but no clear evidence about its expression in mouse, pig, and cow oocytes or cumulus cells is available. We hypothesised that differences in the effect of PLG-PLA system on fertilization results between the species mentioned above could be related to differences in tPA expression. The aim of this study was the detection of mRNA encoding tPA in oocytes and cumulus cells in mouse, pig, and cow by molecular analysis. Total RNA was obtained from oocytes and cumulus cells and cDNA was synthesised with an oligo-dT as primer. These cDNAs were used as template in RT-PCR amplifications using specific primers designed based on the GenBank sequence for Mus musculus, Sus scrofa, and Bos taurus tPA (NM_ 008872, NM_214054, NM_174146, respectively). The results of this study showed a different expression in the 3 studied species. In mouse, amplicon encoding tPA was detected in oocytes and cumulus cells. In cow and pig, tPA transcripts were obtained only in cumulus cells. The relation between the differences in the tPA expression pattern and the role of PLG-PLA system on fertilization remains to be investigated. This study was supported by MICINN (AGL2009-12512-C02-01-02).

scholarly journals Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus

Stroke ◽  
2019 ◽  
Vol 50 (6) ◽  
pp. 1497-1503 ◽  
Author(s):  
Matthew E. Ehrlich ◽  
Li Liang ◽  
Haolin Xu ◽  
Andrzej S. Kosinski ◽  
Adrian F. Hernandez ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Type ◽  
Stroke Patients ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
History Of

Cytosolic Tissue-Type Plasminogen Activator (T-Pa) Levels in Breast Tumors and Hormone Dependence. Role of Ps2

1994 ◽  
Vol 9 (4) ◽  
pp. 251-253 ◽  
Author(s):  
A. Ruibal ◽  
A. Alvarez ◽  
B. Fernández Llana ◽  
Ma Fernández Fernández ◽  
Ma C. Roiz ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Breast Tumors ◽  
Tissue Type ◽  
Hormone Dependence ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator

The Role of the Finger Domain of Tissue-type Plasminogen Activator (t-PA) and Plasminogen Activator Inhibitor 1 (PAI-1) in Initiation and Progression of Thrombolysis

1994 ◽  
Vol 72 (06) ◽  
pp. 900-905 ◽  
Author(s):  
Harold A R Stringer ◽  
Peter van Swieten ◽  
Anton J G Horrevoets ◽  
Annelies Smilde ◽  
Hans Pannekoek
Keyword(s):  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Tissue Type ◽  
Clot Lysis ◽  
Plasminogen Activator Inhibitor 1 ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
Activator Inhibitor ◽  
Pai 1

SummaryWe further investigated the role of the finger (F) and the kringle-2 (K2) domains of tissue-type plasminogen activator (t-PA) in fibrin-stimulated plasminogen activation. To that end, the action of purified (wt) t-PA or of variants lacking F (del.F) or K2 (del.K2) was assessed either in a static, human whole blood clot-lysis system or in whole blood thrombi generated in the “Chandler loop”. In both clot-lysis systems, significant differences were observed for the initiation of thrombolysis with equimolar concentrations of the t-PA variants. A relatively minor “lag phase” occurred in thrombolysis mediated by wt t-PA, whereas a 6.4-fold and 1.6-fold extension is found for del.F and del.K2, respectively. We observed identical lag-times, characteristic for each t-PA variant, in platelet-rich heads and in platelet-poor tails of thrombi. Since plasminogen activator inhibitor 1 (PAI-1) is preferentially retained in the platelet-rich heads, we conclude that the inhibitor does not interfere with the initial stage of thrombolysis but exerts its action in later stages, resulting in a reduction of the rate of clot lysis. A complementation clot-lysis assay was devised to study a potential interplay of del.F and del.K2. Accordingly, clot lysis was determined with combinations of del.F and del.K2 that were inversely varied in relation to equipotent dosage to distinguish between additive, antagonistic or synergistic effects of these variants. The isobole for combinations of del.F and del.K2 shows an independent, additive action of del.F and del.K2 in clot lysis. Under the conditions employed, namely a relatively high concentration of fibrin and Glu-plasminogen and a low concentration of t-PA variant, our data show: i) the crucial role of the F domain and the lack of effect of PAI-1 in initiation of thrombolysis, ii) the lack of importance of the fibrimbinding domains of t-PA and the regulatory role of PAI-1 in advanced stages of thrombolysis.

scholarly journals Emergency Medicine Physicians Accurately Select Acute Stroke Patients for Tissue-Type Plasminogen Activator Treatment Using a Checklist

Stroke ◽  
2020 ◽  
Vol 51 (2) ◽  
pp. 663-665
Author(s):  
Ketevan Berekashvili ◽  
Alicia M. Zha ◽  
Mohammed Abdel-Al ◽  
Xu Zhang ◽  
Jazba H. Soomro ◽  
...  
Keyword(s):  
Emergency Medicine ◽  
Acute Stroke ◽  
Plasminogen Activator ◽  
Tissue Type ◽  
Stroke Patients ◽  
Tissue Type Plasminogen Activator ◽  
Stroke Mimics ◽  
Type Plasminogen Activator ◽  
Emergency Medicine Physician ◽  
Medicine Physician

Background and Purpose— There is uncertainty among many emergency medicine physicians about the decision to give intravenous tPA (tissue-type plasminogen activator), which limits its use. A checklist approach has been suggested as a solution. We compared agreement on tPA treatment in suspected acute ischemic stroke patients between emergency medicine residents (EMRs) using a checklist and vascular neurology fellows (VNFs). Methods— Every suspected acute stroke patient brought to our comprehensive stroke center emergency room within 4.5 hours from symptom onset was prospectively evaluated simultaneously and independently by VNFs and EMRs. The latter used a tPA screening checklist, which included guideline exclusion criteria to help with their treatment decision. Agreement was determined using kappa (k) statistics. Results— Over 6 months, 60 patients were enrolled; 10% large vessel atherosclerosis, 18% cardioembolism, 12% small vessel, 12% cryptogenic, and 47% mimic. Forty-two percent were deemed tPA eligible by the EMR, 30% by the VNF, and 37% by the vascular neurology faculty. There were no complications in any tPA-treated patients. Agreement was substantial between EMR and VNF (κ=0.68 [95% CI, 0.49–0.87]) and between EMR and vascular neurology faculty (κ=0.69 [95% CI, 0.50–0.87]). Stroke mimics were the main cause of disagreement between EMR and VNF (κ=0.24 [95% CI, −0.15 to 0.63]) and between EMR and vascular neurology faculty (κ=0.35 [95% CI, −0.08 to 0.78]). Conclusions— Our data suggest that with the aid of a checklist, EMRs can accurately treat stroke patients with tPA. Areas for improvement include recognition of stroke mimics. Further studies are warranted to evaluate checklist-enhanced tPA treatment to allay emergency medicine physician uncertainty and expand the use of tPA.

Sign in / Sign up

Export Citation Format

Share Document